Clinical Trials
5 trialsNCT07557914 2026-06-03
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT07584018 2026-05-13
The DoHAICs Study Expansion Phase
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07353827 2026-01-20
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07157306 2025-09-05
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06512467 2024-07-22
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting